Chemotherapy and Radiotherapy for Advanced Seminoma
Author Information
Author(s): P.M. Wilkinson, G. Read, B. Magee
Primary Institution: Christie Hospital and Holt Radium Institute
Hypothesis
Can combination chemotherapy improve survival rates in patients with advanced seminoma?
Conclusion
Combination chemotherapy for advanced seminoma resulted in a 5-year survival rate of 49%, with better outcomes for those achieving complete or good partial responses.
Supporting Evidence
- 34 patients were assessable for response, with 24% achieving complete remission.
- Patients with a complete or good partial response had a 66% survival rate at 5 years.
- Survival rates varied by disease stage, with 50% for stage II and 33% for stage IV.
Takeaway
Doctors treated 37 patients with advanced seminoma using chemotherapy and found that many lived longer, especially if their tumors shrank significantly.
Methodology
Patients received either cis-platinum or cyclophosphamide and etoposide, followed by radiotherapy if necessary, with responses assessed after treatment.
Potential Biases
Potential bias due to the non-randomized nature of treatment assignment.
Limitations
The study had a small sample size and relied on historical data for comparison.
Participant Demographics
Median age of participants was 40 years, with a range from 21 to 64 years.
Statistical Information
P-Value
0.001
Statistical Significance
p=0.001
Want to read the original?
Access the complete publication on the publisher's website